PASSAGE BIO INC's ticker is PASG and the CUSIP is 702712100. A total of 75 filers reported holding PASSAGE BIO INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $72,445 | -12.7% | 110,099 | +24.9% | 0.00% | – |
| Q2 2023 | $82,974 | +34.6% | 88,148 | +36.9% | 0.00% | – |
| Q1 2023 | $61,655 | -59.4% | 64,378 | -41.4% | 0.00% | – |
| Q4 2022 | $151,681 | -51.5% | 109,914 | -56.0% | 0.00% | – |
| Q3 2022 | $313,000 | -65.5% | 250,079 | -35.0% | 0.00% | – |
| Q2 2022 | $908,000 | +13.4% | 384,567 | +48.9% | 0.00% | – |
| Q1 2022 | $801,000 | +67.9% | 258,290 | +243.9% | 0.00% | – |
| Q4 2021 | $477,000 | -35.1% | 75,115 | +1.8% | 0.00% | – |
| Q3 2021 | $735,000 | -28.8% | 73,808 | -5.4% | 0.00% | – |
| Q2 2021 | $1,033,000 | -91.3% | 78,029 | -88.5% | 0.00% | -100.0% |
| Q1 2021 | $11,811,000 | +4720.8% | 675,687 | +3524.0% | 0.00% | – |
| Q3 2020 | $245,000 | -60.9% | 18,645 | -18.7% | 0.00% | – |
| Q2 2020 | $627,000 | +213.5% | 22,943 | +80.2% | 0.00% | – |
| Q1 2020 | $200,000 | – | 12,730 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 4,959,769 | $6,200,000 | 10.57% |
| Lynx1 Capital Management LP | 2,752,422 | $3,441,000 | 3.10% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 1,235,869 | $1,545,000 | 2.89% |
| New Leaf Venture Partners, L.L.C. | 2,497,922 | $3,122,000 | 1.85% |
| Frazier Life Sciences Management, L.P. | 3,756,915 | $4,696,000 | 0.36% |
| Orbimed Advisors | 8,931,999 | $11,165,000 | 0.21% |
| Newtyn Management, LLC | 300,000 | $375,000 | 0.08% |
| Deep Track Capital, LP | 1,439,062 | $1,799,000 | 0.08% |
| Rubric Capital Management LP | 822,105 | $1,028,000 | 0.05% |
| Oasis Management Co Ltd. | 240,000 | $300,000 | 0.05% |